The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 6)
In part 6, Prof. Caplan discusses Trophic properties of mesenchymal stem cells; MSCs for heart disease; MSCs homing to heart injury site and also to skin inc...

By: http://www.cellmedicine.com

View original post here:
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 6) - Video

Recommendation and review posted by sam

Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress
Lord John Krebs, chairman of the House of Lords Science and Technology Committee gives his presentation on #39;Mapping a route for the commercialisation of cell...

By: biopharmachannel

Continue reading here:
Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress - Video

Recommendation and review posted by sam

Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine
Ed Field, Chief Operating Officer at Cytomedix gives his presentation on #39;Commercialisation through collaboration: what does partnering in this industry actu...

By: biopharmachannel

Original post:
Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine - Video

Recommendation and review posted by sam

Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013
Prof. Richard Lilford, Clinical Epidemiology, Public Health Biostatistics at the University of Birmingham gives his presentation on #39;Health economics: how ...

By: biopharmachannel

Read more:
Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013 - Video

Recommendation and review posted by sam

World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Continue reading here:
World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013 - Video

Recommendation and review posted by sam

Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress
Navid Malik, Head of Life Science Research at Cenkos Securities gives his presentation on #39;Alternative financing models: floating on the stock markets to gai...

By: biopharmachannel

Go here to read the rest:
Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress - Video

Recommendation and review posted by sam

Chairman #39;s Opening Remarks - Prof. Chris Mason - World Stem Cells Regenerative Medicine Congress
Prof. Chris Mason from the Regenerative Medicine Bioprocessing Unit, Advanced Centre for Biochemical Engineering at the University College London gives the C...

By: biopharmachannel

More here:
Chairman's Opening Remarks - Prof. Chris Mason - World Stem Cells Regenerative Medicine Congress - Video

Recommendation and review posted by sam

GOODIEMOB with Cee-Lo Performing LIVE "Cell Therapy"
The Atlanta Hip Hop group, GOODIEMOB, performs in Hollywood. Original member and "The Voice #39;s" Cee-Lo Green performs their rap music hit, "Cell Therapy", wit...

By: ellenoir1

View post:
GOODIEMOB with Cee-Lo Performing LIVE "Cell Therapy" - Video

Recommendation and review posted by Bethany Smith

Public release date: 23-Jun-2013 [ | E-mail | Share ]

Contact: Sue McGreevey smcgreevey@partners.org 617-724-2764 Massachusetts General Hospital

In the past year a group of synthetic proteins called CRISPR-Cas RNA-guided nucleases (RGNs) have generated great excitement in the scientific community as gene-editing tools. Exploiting a method that some bacteria use to combat viruses and other pathogens, CRISPR-Cas RGNs can cut through DNA strands at specific sites, allowing the insertion of new genetic material. However, a team of Massachusetts General Hospital (MGH) researchers has found a significant limitation to the use of CRISPR-Cas RGNs, production of unwanted DNA mutations at sites other than the desired target.

"We found that expression of CRISPR-Cas RGNs in human cells can have off-target effects that, surprisingly, can occur at sites with significant sequence differences from the targeted DNA site," says J. Keith Joung, MD, PhD, associate chief for Research in the Massachusetts General Hospital (MGH) Department of Pathology and co-senior author of the report receiving online publication in Nature Biotechnology. "RGNs continue to have tremendous advantages over other genome editing technologies, but these findings have now focused our work on improving their precision."

Consisting of a DNA-cutting enzyme called Cas 9, coupled with a short, 20-nucleotide segment of RNA that matches the target DNA segment, CRISPR-Cas RGNs mimic the primitive immune systems of certain bacteria. When these microbes are infected by viruses or other organisms, they copy a segment of the invader's genetic code and incorporate it into their DNA, passing it on to future bacterial generations. If the same pathogen is encountered in the future, the bacterial enzyme called Cas9, guided by an RNA sequence the matches the copied DNA segment, inactivates the pathogen by cutting its DNA at the target site.

About a year ago, scientists reported the first use of programmed CRISPR-Cas RGNs to target and cut specific DNA sites. Since then several research teams, including Joung's, have succesfully used CRISPR-Cas RGNs to make genomic changes in fruit flies, zebrafish, mice and in human cells including induced pluripotent stem cells which have many of the characteristics of embryonic stem cells. The technology's reliance on such a short RNA segment makes CRISPR-Cas RGNs much easier to use than other gene-editing tools called zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), and RGNs can be programmed to introduce several genetic changes at the same time.

However, the possibility that CRISPR-Cas RGNs might cause additional, unwanted genetic changes has been largely unexplored, so Joung's team set out to investigate the occurrence of "off-target" mutations in human cells expressing CRISPR-Cas RGNs. Since the interaction between the guiding RNA segment and the target DNA relies on only 20 nucleotides, they hypothesized that the RNA might also recognize DNA segments that differed from the target by a few nucleotides.

Although previous studies had found that a single-nucleotide mismatch could prevent the action of some CRISPR-Cas RGNs, the MGH team's experiments in human cell lines found multiple instances in which mismatches of as many as five nucleotides did not prevent cleavage of an off-target DNA segment. They also found that the rates of mutation at off-target sites could be as high or even higher than at the targeted site, something that has not been observed with off-target mutations associated with ZFNs or TALENs.

"Our results don't mean that RGNs cannot be important research tools, but they do mean that researchers need to account for these potentially confounding effects in their experiments. They also suggest that the existing RGN platform may not be ready for therapeutic applications," says Joung, who is an associate professor of Pathology at Harvard Medical School. "We are now working on ways to reduce these off-target effects, along with methods to identify all potential off-target sites of any given RGN in human cells so that we can assess whether any second-generation RGN platforms that are developed will be actually more precise on a genome-wide scale. I am optimistic that we can further engineer this system to achieve greater specificity so that it might be used for therapy of human diseases."

###

Read the original here:
Powerful gene-editing tool appears to cause off-target mutations in human cells

Recommendation and review posted by Bethany Smith

Genetic Engineering and Glowing Kitties of DOOM!
In this video Nega looks at one of the examples of genetic modification gone wild. Genetic Modification Gone Wild: 10 Signs That Our World May Be Destined To...

By: Myles Power (powerm1985)

More:
Genetic Engineering and Glowing Kitties of DOOM! - Video

Recommendation and review posted by Bethany Smith

Shark Antibodies and Genetic Engineering
La Trobe University Project.

By: Malikah McEwen

The rest is here:
Shark Antibodies and Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

Genius, Mental Illness and Everything in Between: Dr. Lamont Tang at TEDxHongKongED
To what extent is genius and mental illness such as bipolar disorder and schizophrenia related? To what extent do genetics and environment influence genius a...

By: TEDxTalks

Original post:
Genius, Mental Illness and Everything in Between: Dr. Lamont Tang at TEDxHongKongED - Video

Recommendation and review posted by Bethany Smith

LUGANO, Switzerland--(BUSINESS WIRE)--

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS (brentuximab vedotin) versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma (HL) post-autologous stem cell transplant (ASCT) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma (ICML) being held June 1922, 2013 in Lugano, Switzerland.

ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and sALCL.

The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. The post-hoc analysis was conducted in patients with relapsed or refractory HL post-ASCT or relapsed or refractory sALCL in the intent-to-treat (ITT) population. It also included prior systemic treatment histories and post-ADCETRIS stem cell transplant experience for each patient in the ITT populations.

These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population, said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.

Progression-free survival analyses of two pivotal phase 2 studies of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma (Poster #303)

The analysis, presented by Dr. Radford, included:

Relapsed or Refractory HL post-ASCT

Relapsed or Refractory sALCL

Details of the poster presentation are as follows:

Link:
Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® ...

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations at the 12th International Conference on Malignant Lymphoma (ICML) being held June 19-22, 2013 in Lugano, Switzerland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL and conditional marketing authorization by the European Commission in October 2012 for relapsed or refractory HL and relapsed or refractory sALCL. Four oral and two poster presentations at ICML illustrated the broad clinical development program for ADCETRIS, including oral presentations describing the ongoing global phase 3 ECHELON-2 trial in frontline mature T-cell lymphoma (MTCL) and data from a phase 2 trial in patients with relapsed MTCL. In addition, an oral presentation included the first report of data from an investigator-sponsored trial evaluating ADCETRIS in first-relapse HL patients as part of a pre-autologous stem cell transplant regimen.

With last years European conditional marketing authorization supporting the use of ADCETRIS as a treatment for patients with relapsed HL and sALCL, this meeting provides us with an opportunity to share important ADCETRIS data with the international physician and patient community as we evaluate ADCETRIS in additional disease settings, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. ADCETRIS is being evaluated for the treatment of CD30-positive malignancies in more than 20 ongoing clinical trials, including three global phase 3 trials. We look forward to the ongoing presentation of important data at medical meetings such as ICML, demonstrating the broad therapeutic potential of ADCETRIS.

Oral Presentations

PET-adapted Sequential Therapy with Brentuximab Vedotin and Augmented-ICE in Relapsed and Refractory Hodgkin Lymphoma (Abstract #141, oral session on Saturday, June 22, 2013 at 8:50 AM CET)

In an ongoing investigator-sponsored phase 2 clinical trial, patients with relapsed or refractory HL have been enrolled to determine whether ADCETRIS can replace the combination chemotherapy regimen ifosfamide, carboplatin and etoposide (ICE) or be used in sequential administration with ICE to increase the rate of pre-transplant FDG-PET normalization (PET-N), which is an important prognostic factor for patients undergoing autologous stem cell transplant (ASCT). At the time of data analysis, 40 patients had been enrolled and 33 patients had completed the treatment program. Key findings presented by Dr. Alison Moskowitz from Memorial Sloan Kettering Cancer Center include:

ADCETRIS is not approved for salvage HL patients who are deemed eligible for ASCT.

Safety and Efficacy of Brentuximab Vedotin for the Treatment of Relapsed Mature T-/NK-Cell Lymphomas (Abstract #152, oral session on Saturday, June 22, 2013 at 10:00 AM CET)

In an encore presentation from the 2012 American Society of Hematology (ASH) Annual Meeting, data were highlighted from a subset of patients in an ongoing phase 2 clinical trial evaluating ADCETRIS in CD30-positive non-Hodgkin lymphoma. The trial is designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients. At the time of data analysis, 29 patients with MTCL had been enrolled, including 11 with angioimmunoblastic T-cell lymphoma (AITL) and 18 with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). The median number of prior systemic therapies in both lymphoma classifications was two. Key findings include:

ADCETRIS is not approved for the treatment of the MTCL subtypes described in this presentation.

Excerpt from:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at International Conference on Malignant ...

Recommendation and review posted by Bethany Smith

Seven-year-old Emily Whitehead received a lot of attention last year when a gene therapy engineered at the University of Pennsylvania cured her of leukemia. At the time, Emily was one of 10 patients who received the T cell therapy that uses a patient's own healthy T cells infected with a virus to attack the cancer cells.

What's really interesting about the therapy is that it uses the HIV virus. How is that possible?

"The virus has been engineered so that it can't cause disease anymore, but it still retains the ability to reprogram the immune system so that it will now attack cancer cells," says Carl H. June, MD from the University of Pennsylvania.

The new cells have been nicknamed "serial killer cells," and rightfully so. These modified cells can kill more than 1,000 different tumor cells.

Check out the video below for more about Emily Whitehead and how the T cell gene therapy works.

Read the original:
HIV virus behind leukemia cures at Children's Hospital of Philadelphia

Recommendation and review posted by Bethany Smith

Ovation Cell Therapy Review
Ovation Cell Therapy claims to improve hair thickness, length and overall health of your hair. Link for more info below: http://ovationhair.com/cell-therapy....

By: Starlette223

Continued here:
Ovation Cell Therapy Review - Video

Recommendation and review posted by Bethany Smith

First dog on Oahu gets stem cell therapy
A 13-year-old dog who was barely able to walk is back on his paws thanks to stem cell therapy. Before the treatment Kumba suffered from arthritis so bad he c...

By: Joem Costes

Read more:
First dog on Oahu gets stem cell therapy - Video

Recommendation and review posted by Bethany Smith

WEDNESDAY, June 19 (HealthDay News) -- Could screening for colon cancer someday be as easy as having a blood test? Researchers say just such a test is showing early promise in trials.

The screening checks for levels of miR-21 -- a piece of DNA known as microRNA. Researchers in the gastrointestinal cancer research lab at the Baylor Research Institute in Dallas studied several hundred patients with either colorectal polyps (noncancerous growths that often precede cancer) or full-blown cancer.

They found that measuring levels of miR-21 in the blood accurately spotted up to 92 percent of patients with colorectal cancer.

The test also accurately identified up to 82 percent of patients with advanced colorectal polyps -- growths that put people at high risk of developing colorectal cancer.

The study was published June 19 in the Journal of the National Cancer Institute.

"This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars," Dr. Michael Ramsay, president of Baylor Research Institute, said in an institute news release.

Other experts were cautiously optimistic.

"These results are very promising for the future of cancer screening and treatment," said Dr. Jerald Wishner, director of colorectal surgery at Northern Westchester Hospital in Mount Kisco, N.Y.

"Colonoscopy screening is the current gold standard to detect colon cancer. However, less than 50 percent of Americans who should be screened get screened," Wishner said. "The blood test is a less invasive screening method that will eliminate barriers to colonoscopies, including embarrassment and possible discomfort in preparation for the test."

Dr. David Robbins, associate chief of endoscopy at Lenox Hill Hospital in New York City, agreed that it is "only a matter of time before we can screen for the most common, and most lethal, cancers using a simple blood test."

See the rest here:
Gene-Based Blood Test for Colon Cancer Shows Promise

Recommendation and review posted by Bethany Smith

Public release date: 20-Jun-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 20, 2013At least half of all cases of deafness that develop from birth through infancy in developed countries have a genetic basis, as do many cases of later onset progressive hearing loss. To date, at least 1,000 mutations occurring in 64 genes in the human genome have been linked to hearing loss. Next-generation DNA sequencing technologies are enabling the identification of these deafness-causing genetic variants, as described in a Review article in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Genetic Testing and Molecular Biomarkers website.

In "Next-Generation Sequencing in Genetic Hearing Loss," Denise Yan and Xue Zhong Liu, University of Miami (Florida), and Mustafa Tekin and Susan Blanton, University of Miami Miller School of Medicine, review the advances in high-throughput, massively parallel DNA sequencing that amplify and repeatedly sequence only specific regions of the human genome in which genes linked to deafness are likely to be found. This strategy, known as "targeted resequencing," allows researchers to find disease-related gene mutations much more quickly than searching through the entire genome. To date at least 1,000 DNA variants at more than 130 sites in the human genome have been identified that can cause hearing loss not associated with other symptoms or syndromes.

"Over the next decade, most of the variant genes responsible for deafness will be identified and such knowledge will lead to the development of practical treatments," conclude the authors.

"Knowledge of the genetic lesions underlying deafness will greatly assist development of targeted therapy," says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida's Genetics Institute, College of Medicine, Gainesville, FL.

###

About the Journal

Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published 12 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of content and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.

About the Publisher

Read this article:
Goal of identifying nearly all genetic causes of deafness is within reach

Recommendation and review posted by Bethany Smith

Before I stumbled across vegangmo.com the other day I thought I knew the arguments for and against genetically-engineered crops.

The Vegan GMO website showed me I don't know as much as I thought. The site's "why are we vegans pro GMO?" page (http://www.vegangmo.com) lists four reasons, three of which were new to me:

-- Some safety tests for GE crops involve animal experiments;

-- Genetic engineering could create "animal alternative" foods that would encourage more veganism, like artificial cheese;

-- Genetic engineering could create plants containing nutrients vegans lack, like vitamin B12 and DHA;

-- GE crops use less fertilizer and pesticides, so fewer insects and fish are killed, and "no- or low-till agriculture will save the lives of ground-dwelling animals."

It was the first reason -- opposition to animal tests -- that led me to the site. I had been reading up on a study purporting to show that pigs consuming genetically-engineered corn and soybeans had developed health problems. Vegan GMO had quoted (http://www.vegangmo.com), a rebuttal charging that "this study subjects animals to inhumanely poor conditions resulting in health impacts which can then be data-mined to present 'evidence' against GMO feeds."

The rebuttal, by British environmentalist and recent pro-GE convert Mark Lynas, leveled other broadsides at the study (http://tiny.cc/). It noted that while the study's authors highlighted one measure on which the GE-fed pigs scored worse than those on conventional feed, on several health measures the GE-fed pigs had scored better.

As you might expect, though, the vegan website's excerpt from the Lynas rebuttal stuck with the animal-cruelty argument.

"Most damning of all," the excerpt continued, "close to 60% of both sets of pigs were suffering from pneumonia at the time of slaughter -- another classic indicator of bad husbandry. Had they not been slaughtered, all these pigs might well have died quickly anyway. No conclusions can be drawn from this study, except for one -- that there should be tighter controls on experiments performed on animals by anti-biotech campaigners, for the sake of animal welfare."

Read this article:
Vegans Who Favor Genetic Engineering

Recommendation and review posted by Bethany Smith

London, June 21 (ANI): Researchers believe that most of the variant genes responsible for deafness will be identified over the next decade and such knowledge will lead to the development of practical treatments.

At least half of all cases of deafness that develop from birth through infancy in developed countries have a genetic basis, as do many cases of later onset progressive hearing loss.

To date, at least 1,000 mutations occurring in 64 genes in the human genome have been linked to hearing loss.

A new article has revealed that next-generation DNA sequencing technologies are enabling the identification of these deafness-causing genetic variants.

In "Next-Generation Sequencing in Genetic Hearing Loss," Denise Yan and Xue Zhong Liu, University of Miami (Florida), and Mustafa Tekin and Susan Blanton, University of Miami Miller School of Medicine, review the advances in high-throughput, massively parallel DNA sequencing that amplify and repeatedly sequence only specific regions of the human genome in which genes linked to deafness are likely to be found.

This strategy, known as "targeted resequencing," allows researchers to find disease-related gene mutations much more quickly than searching through the entire genome. To date at least 1,000 DNA variants at more than 130 sites in the human genome have been identified that can cause hearing loss not associated with other symptoms or syndromes.

The Review article appeared in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. (ANI)

Here is the original post:
Nearly all genetic causes of deafness could be identified soon

Recommendation and review posted by Bethany Smith

Editor's Choice Academic Journal Main Category: Hearing / Deafness Also Included In: Genetics Article Date: 21 Jun 2013 - 0:00 PDT

Current ratings for: Deafness - Identifying All Genetic Causes Within Reach

According to WHO (World Health Organization), more than 360 million people worldwide live with disabling hearing loss.

So far, geneticists have identified 1,000 mutations in 64 genes in the human genome that have been associated with deafness.

The authors explained that next-generation DNA sequencing technologies are accelerating the identification of genetic variants that cause deafness.

In this latest report - "Next Generation Sequencing in Genetic Hearing Loss" - Susan Blanton, Mustafa Tekin, Xue Zhong Liu and Denise Yan gathered and examined data on the advances in high-throughput, massively parallel DNA sequencing that amplify and repeatedly sequence only certain regions of the human genome where genes associated with hearing loss are probably located.

This strategy is called "targeted resequencing". Scientists are able to locate disease-related gene mutations much faster than searching through the whole genome.

So far, over 1,000 DNA variants at over 130 sites in the human genome that have been identified to cause hearing loss and are not linked to any other symptoms or syndromes have been located.

The authors wrote:

Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers said "Knowledge of the genetic lesions underlying deafness will greatly assist development of targeted therapy."

See the rest here:
Deafness - Identifying All Genetic Causes Within Reach

Recommendation and review posted by Bethany Smith

genetics,hate,primal instincts,epigenetics and blind breeding.
understand that what I am talking about is not fully researched but also is not ment at all to advocate for forced eugenics. what might benifit us most is kn...

By: TheBadcop69

Go here to see the original:
genetics,hate,primal instincts,epigenetics and blind breeding. - Video

Recommendation and review posted by Bethany Smith

Clinton: SCOTUS Myriad Genetics Decision #39;Terrific #39;
June 14 (Bloomberg) -- Former President Bill Clinton discusses the U.S. Supreme Court #39;s decision in Association for Molecular Pathology v. Myriad Genetics, I...

By: Bloomberg Law

See more here:
Clinton: SCOTUS Myriad Genetics Decision 'Terrific' - Video

Recommendation and review posted by Bethany Smith

Genetics Sex linked Traits
Genetics Sex linked Traits.

By: Jack aNerd

Read more:
Genetics Sex linked Traits - Video

Recommendation and review posted by Bethany Smith